• 1
    Brunner KT,Mauel J,Cerottini JC,Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro: Inhibition by isoantibody and by drugs. Immunology 1968; 14: 181196.
  • 2
    Brown CE,Wright CL,Naranjo A,Vishwanath RP,Chang WC,Olivares S,Wagner JR,Bruins L,Raubitschek A,Cooper LJ, Jensen MC. Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods 2005; 297: 3952.
  • 3
    van Baalen CA,Kwa D,Verschuren EJ,Reedijk ML,Boon AC,de Mutsert G,Rimmelzwaan GF,Osterhaus AD,Gruters RA. Fluorescent antigen-transfected target cell cytotoxic T lymphocyte assay for ex vivo detection of antigen-specific cell-mediated cytotoxicity. J Infect Dis 2005; 192: 11831190.
  • 4
    Kloss S,Bochennek K,Huenecke S,Zimmermann SY,Kuci S,Muller T,Wels WS,Klingebiel T,Esser R,Koehl U. A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells. J Immunol Methods 2007; 325: 140147.
  • 5
    Kim GG,Donnenberg VS,Donnenberg AD,Gooding W,Whiteside TL. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: Comparisons to a 4 h 51Cr-release assay. J Immunol Methods 2007; 325: 5166.
  • 6
    Piriou L,Chilmonczyk S,Genetet N,Albina E. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 2000; 41: 289297.
  • 7
    Godoy-Ramirez K,Makitalo B,Thorstensson R,Sandstrom E,Biberfeld G,Gaines H. A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry. Cytometry A 2005; 68A: 7180.
  • 8
    Mittendorf EA,Storrer CE,Shriver CD,Ponniah S,Peoples GE. Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides. Breast Cancer Res Treat 2005; 92: 8593.
  • 9
    Betts MR,Brenchley JM,Price DA,De Rosa SC,Douek DC,Roederer M,Koup RA. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 6578.
  • 10
    Rubio V,Stuge TB,Singh N,Betts MR,Weber JS,Roederer M,Lee PP. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003; 9: 13771382.
  • 11
    Alter G,Malenfant JM,Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294: 1522.
  • 12
    Penack O,Gentilini C,Fischer L,Asemissen AM,Scheibenbogen C,Thiel E,Uharek L. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 2005; 19: 835840.
  • 13
    Hermans IF,Silk JD,Yang J,Palmowski MJ,Gileadi U,McCarthy C,Salio M,Ronchese F,Cerundolo V. The VITAL assay: A versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods 2004; 285: 2540.
  • 14
    Sheehy ME,McDermott AB,Furlan SN,Klenerman P,Nixon DF. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 2001; 249: 99110.
  • 15
    Metelitsa LS. Flow cytometry for natural killer T cells: Multi-parameter methods for multifunctional cells. Clin Immunol 2004; 110: 267276.
  • 16
    Seder RA,Darrah PA,Roederer M. T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol 2008; 8: 247258.
  • 17
    Langhans B,Ahrendt M,Nattermann J,Sauerbruch T,Spengler U. Comparative study of NK cell-mediated cytotoxicity using radioactive and flow cytometric cytotoxicity assays. J Immunol Methods 2005; 306: 161168.
  • 18
    Cooper LJ,Ausubel L,Gutierrez M,Stephan S,Shakeley R,Olivares S,Serrano LM,Burton L,Jensen MC,Forman SJ, et al. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 2006; 8: 105117.
  • 19
    Gabrielsson J, Weiner D. Pharmacokinetic and pharmaocodynamic data analysis: Concepts and applications, 2nd edition. 1997; Apotekarsocieteten: The Swedish Pharmaceutical Society, The Swedish Pharmaceutical Press.
  • 20
    Pinheiro JC, Bates DM. Mixed Effects Models in S and S-Plus. New York: Springer; 2000.
  • 21
    Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
  • 22
    Pavone L,Fanti G,Bongiovanni C,Goldoni M,Alberici F,Bonomini S,Cristinelli L,Buzio C. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma. Med Oncol 2009; 26: 3844.
  • 23
    Molto L,Carballido J,Manzano L,Martinez-Martin B,Esquivel F,Chafer J,Olivier C,Alvarez-Mon M. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2. J Immunother 1999; 22: 260267.
  • 24
    Farace F,Angevin E,Dietrich PY,Leboullaire C,Vanderplancke J,Escudier B,Triebel F. Low-dose IL-2 treatment: Activation of discrete T- and NK-cell sub-populations in vivo. Int J Cancer 1995; 62: 523528.
  • 25
    Harari A,Vallelian F,Meylan PR,Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. JImmunol 2005; 174: 10371045.
  • 26
    Darrah PA,Patel DT,De Luca PM,Lindsay RW,Davey DF,Flynn BJ,Hoff ST,Andersen P,Reed SG,Morris SL, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13: 843850.
  • 27
    Betts MR,Nason MC,West SM,De Rosa SC,Migueles SA,Abraham J,Lederman MM,Benito JM,Goepfert PA,Connors M, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107: 47814789.